NCT07413939 2026-03-10
BREnnA
Hoffmann-La Roche
Phase 2/3 Not yet recruiting
Clinical Trials
5 trialsNCT03975647 2025-12-10
A Study of Tucatinib vs. Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Patients With Advanced or Metastatic HER2+ Breast Cancer
Seagen Inc.
Phase 3 Active not recruiting
NCT05253911 2025-12-04
TRACE
iOMEDICO AG
Completed
NCT04220203 2025-06-26
Treatment Protocol of Tucatinib With Capecitabine and Trastuzumab in Patients With Unresectable Previously Treated HER2+ Breast Cancer
Seagen Inc.
Approved for marketing
NCT05955170 2025-03-27
TUC-TOC
Institut Curie
Phase 2 Recruiting